

Global Communicable Diseases Drugs Market Research Report 2024, Forecast to 2032

https://marketpublishers.com/r/G6C4E197AAC5EN.html

Date: October 2024

Pages: 153

Price: US\$ 3,400.00 (Single User License)

ID: G6C4E197AAC5EN

Abstracts

Report Overview

In this report, we study the drugs for Communicable Diseases. Communicable diseases are disorders caused by organisms — such as bacteria, viruses, fungi or parasites

The global Communicable Diseases Drugs market size was estimated at USD 28160 million in 2023 and is projected to reach USD 50055.00 million by 2032, exhibiting a CAGR of 6.60% during the forecast period.

North America Communicable Diseases Drugs market size was estimated at USD 8191.38 million in 2023, at a CAGR of 5.66% during the forecast period of 2024 through 2032.

This report provides a deep insight into the global Communicable Diseases Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Communicable Diseases Drugs Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors



and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Communicable Diseases Drugs market in any manner.


Global Communicable Diseases Drugs Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company
Novartis
Gilead
GSK
Roche
Merck
Boehringer Ingelheim
Eli Lilly
AstraZeneca
J&J
Teva

AbbVie







North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Communicable Diseases Drugs Market

Overview of the regional outlook of the Communicable Diseases Drugs Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your



competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support



Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Communicable Diseases Drugs Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.



Chapter 9 shares the main producing countries of Communicable Diseases Drugs, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.

Chapter 13 is the main points and conclusions of the report.



Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

- 1.1 Market Definition and Statistical Scope of Communicable Diseases Drugs
- 1.2 Key Market Segments
 - 1.2.1 Communicable Diseases Drugs Segment by Type
 - 1.2.2 Communicable Diseases Drugs Segment by Application
- 1.3 Methodology & Sources of Information
 - 1.3.1 Research Methodology
 - 1.3.2 Research Process
- 1.3.3 Market Breakdown and Data Triangulation
- 1.3.4 Base Year
- 1.3.5 Report Assumptions & Caveats

2 COMMUNICABLE DISEASES DRUGS MARKET OVERVIEW

- 2.1 Global Market Overview
- 2.1.1 Global Communicable Diseases Drugs Market Size (M USD) Estimates and Forecasts (2019-2032)
- 2.1.2 Global Communicable Diseases Drugs Sales Estimates and Forecasts
 (2019-2032)
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region

3 COMMUNICABLE DISEASES DRUGS MARKET COMPETITIVE LANDSCAPE

- 3.1 Global Communicable Diseases Drugs Sales by Manufacturers (2019-2024)
- 3.2 Global Communicable Diseases Drugs Revenue Market Share by Manufacturers (2019-2024)
- 3.3 Communicable Diseases Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.4 Global Communicable Diseases Drugs Average Price by Manufacturers (2019-2024)
- 3.5 Manufacturers Communicable Diseases Drugs Sales Sites, Area Served, Product Type
- 3.6 Communicable Diseases Drugs Market Competitive Situation and Trends
 - 3.6.1 Communicable Diseases Drugs Market Concentration Rate
 - 3.6.2 Global 5 and 10 Largest Communicable Diseases Drugs Players Market Share



by Revenue

3.6.3 Mergers & Acquisitions, Expansion

4 COMMUNICABLE DISEASES DRUGS INDUSTRY CHAIN ANALYSIS

- 4.1 Communicable Diseases Drugs Industry Chain Analysis
- 4.2 Market Overview of Key Raw Materials
- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF COMMUNICABLE DISEASES DRUGS MARKET

- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Market Restraints
- 5.5 Industry News
 - 5.5.1 New Product Developments
 - 5.5.2 Mergers & Acquisitions
 - 5.5.3 Expansions
- 5.5.4 Collaboration/Supply Contracts
- 5.6 Industry Policies

6 COMMUNICABLE DISEASES DRUGS MARKET SEGMENTATION BY TYPE

- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
- 6.2 Global Communicable Diseases Drugs Sales Market Share by Type (2019-2024)
- 6.3 Global Communicable Diseases Drugs Market Size Market Share by Type (2019-2024)
- 6.4 Global Communicable Diseases Drugs Price by Type (2019-2024)

7 COMMUNICABLE DISEASES DRUGS MARKET SEGMENTATION BY APPLICATION

- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Communicable Diseases Drugs Market Sales by Application (2019-2024)
- 7.3 Global Communicable Diseases Drugs Market Size (M USD) by Application (2019-2024)



7.4 Global Communicable Diseases Drugs Sales Growth Rate by Application (2019-2024)

8 COMMUNICABLE DISEASES DRUGS MARKET CONSUMPTION BY REGION

- 8.1 Global Communicable Diseases Drugs Sales by Region
 - 8.1.1 Global Communicable Diseases Drugs Sales by Region
 - 8.1.2 Global Communicable Diseases Drugs Sales Market Share by Region
- 8.2 North America
 - 8.2.1 North America Communicable Diseases Drugs Sales by Country
 - 8.2.2 U.S.
 - 8.2.3 Canada
 - 8.2.4 Mexico
- 8.3 Europe
 - 8.3.1 Europe Communicable Diseases Drugs Sales by Country
 - 8.3.2 Germany
 - 8.3.3 France
 - 8.3.4 U.K.
 - 8.3.5 Italy
 - 8.3.6 Russia
- 8.4 Asia Pacific
 - 8.4.1 Asia Pacific Communicable Diseases Drugs Sales by Region
 - 8.4.2 China
 - 8.4.3 Japan
 - 8.4.4 South Korea
 - 8.4.5 India
 - 8.4.6 Southeast Asia
- 8.5 South America
 - 8.5.1 South America Communicable Diseases Drugs Sales by Country
 - 8.5.2 Brazil
 - 8.5.3 Argentina
 - 8.5.4 Columbia
- 8.6 Middle East and Africa
 - 8.6.1 Middle East and Africa Communicable Diseases Drugs Sales by Region
 - 8.6.2 Saudi Arabia
 - 8.6.3 UAE
 - 8.6.4 Egypt
 - 8.6.5 Nigeria
 - 8.6.6 South Africa



9 COMMUNICABLE DISEASES DRUGS MARKET PRODUCTION BY REGION

- 9.1 Global Production of Communicable Diseases Drugs by Region (2019-2024)
- 9.2 Global Communicable Diseases Drugs Revenue Market Share by Region (2019-2024)
- 9.3 Global Communicable Diseases Drugs Production, Revenue, Price and Gross Margin (2019-2024)
- 9.4 North America Communicable Diseases Drugs Production
- 9.4.1 North America Communicable Diseases Drugs Production Growth Rate (2019-2024)
- 9.4.2 North America Communicable Diseases Drugs Production, Revenue, Price and Gross Margin (2019-2024)
- 9.5 Europe Communicable Diseases Drugs Production
 - 9.5.1 Europe Communicable Diseases Drugs Production Growth Rate (2019-2024)
- 9.5.2 Europe Communicable Diseases Drugs Production, Revenue, Price and Gross Margin (2019-2024)
- 9.6 Japan Communicable Diseases Drugs Production (2019-2024)
 - 9.6.1 Japan Communicable Diseases Drugs Production Growth Rate (2019-2024)
- 9.6.2 Japan Communicable Diseases Drugs Production, Revenue, Price and Gross Margin (2019-2024)
- 9.7 China Communicable Diseases Drugs Production (2019-2024)
 - 9.7.1 China Communicable Diseases Drugs Production Growth Rate (2019-2024)
- 9.7.2 China Communicable Diseases Drugs Production, Revenue, Price and Gross Margin (2019-2024)

10 KEY COMPANIES PROFILE

- 10.1 Novartis
- 10.1.1 Novartis Communicable Diseases Drugs Basic Information
- 10.1.2 Novartis Communicable Diseases Drugs Product Overview
- 10.1.3 Novartis Communicable Diseases Drugs Product Market Performance
- 10.1.4 Novartis Business Overview
- 10.1.5 Novartis Communicable Diseases Drugs SWOT Analysis
- 10.1.6 Novartis Recent Developments
- 10.2 Gilead
 - 10.2.1 Gilead Communicable Diseases Drugs Basic Information
 - 10.2.2 Gilead Communicable Diseases Drugs Product Overview
 - 10.2.3 Gilead Communicable Diseases Drugs Product Market Performance



- 10.2.4 Gilead Business Overview
- 10.2.5 Gilead Communicable Diseases Drugs SWOT Analysis
- 10.2.6 Gilead Recent Developments

10.3 GSK

- 10.3.1 GSK Communicable Diseases Drugs Basic Information
- 10.3.2 GSK Communicable Diseases Drugs Product Overview
- 10.3.3 GSK Communicable Diseases Drugs Product Market Performance
- 10.3.4 GSK Communicable Diseases Drugs SWOT Analysis
- 10.3.5 GSK Business Overview
- 10.3.6 GSK Recent Developments

10.4 Roche

- 10.4.1 Roche Communicable Diseases Drugs Basic Information
- 10.4.2 Roche Communicable Diseases Drugs Product Overview
- 10.4.3 Roche Communicable Diseases Drugs Product Market Performance
- 10.4.4 Roche Business Overview
- 10.4.5 Roche Recent Developments

10.5 Merck

- 10.5.1 Merck Communicable Diseases Drugs Basic Information
- 10.5.2 Merck Communicable Diseases Drugs Product Overview
- 10.5.3 Merck Communicable Diseases Drugs Product Market Performance
- 10.5.4 Merck Business Overview
- 10.5.5 Merck Recent Developments

10.6 Boehringer Ingelheim

- 10.6.1 Boehringer Ingelheim Communicable Diseases Drugs Basic Information
- 10.6.2 Boehringer Ingelheim Communicable Diseases Drugs Product Overview
- 10.6.3 Boehringer Ingelheim Communicable Diseases Drugs Product Market

Performance

- 10.6.4 Boehringer Ingelheim Business Overview
- 10.6.5 Boehringer Ingelheim Recent Developments

10.7 Eli Lilly

- 10.7.1 Eli Lilly Communicable Diseases Drugs Basic Information
- 10.7.2 Eli Lilly Communicable Diseases Drugs Product Overview
- 10.7.3 Eli Lilly Communicable Diseases Drugs Product Market Performance
- 10.7.4 Eli Lilly Business Overview
- 10.7.5 Eli Lilly Recent Developments

10.8 AstraZeneca

- 10.8.1 AstraZeneca Communicable Diseases Drugs Basic Information
- 10.8.2 AstraZeneca Communicable Diseases Drugs Product Overview
- 10.8.3 AstraZeneca Communicable Diseases Drugs Product Market Performance



- 10.8.4 AstraZeneca Business Overview
- 10.8.5 AstraZeneca Recent Developments
- 10.9 J and J
- 10.9.1 J and J Communicable Diseases Drugs Basic Information
- 10.9.2 J and J Communicable Diseases Drugs Product Overview
- 10.9.3 J and J Communicable Diseases Drugs Product Market Performance
- 10.9.4 J and J Business Overview
- 10.9.5 J and J Recent Developments
- 10.10 Teva
- 10.10.1 Teva Communicable Diseases Drugs Basic Information
- 10.10.2 Teva Communicable Diseases Drugs Product Overview
- 10.10.3 Teva Communicable Diseases Drugs Product Market Performance
- 10.10.4 Teva Business Overview
- 10.10.5 Teva Recent Developments
- 10.11 AbbVie
 - 10.11.1 AbbVie Communicable Diseases Drugs Basic Information
 - 10.11.2 AbbVie Communicable Diseases Drugs Product Overview
 - 10.11.3 AbbVie Communicable Diseases Drugs Product Market Performance
 - 10.11.4 AbbVie Business Overview
- 10.11.5 AbbVie Recent Developments
- 10.12 Bausch Health
- 10.12.1 Bausch Health Communicable Diseases Drugs Basic Information
- 10.12.2 Bausch Health Communicable Diseases Drugs Product Overview
- 10.12.3 Bausch Health Communicable Diseases Drugs Product Market Performance
- 10.12.4 Bausch Health Business Overview
- 10.12.5 Bausch Health Recent Developments
- 10.13 Abbott
- 10.13.1 Abbott Communicable Diseases Drugs Basic Information
- 10.13.2 Abbott Communicable Diseases Drugs Product Overview
- 10.13.3 Abbott Communicable Diseases Drugs Product Market Performance
- 10.13.4 Abbott Business Overview
- 10.13.5 Abbott Recent Developments
- 10.14 Sanofi
- 10.14.1 Sanofi Communicable Diseases Drugs Basic Information
- 10.14.2 Sanofi Communicable Diseases Drugs Product Overview
- 10.14.3 Sanofi Communicable Diseases Drugs Product Market Performance
- 10.14.4 Sanofi Business Overview
- 10.14.5 Sanofi Recent Developments
- 10.15 Sun Pharma



- 10.15.1 Sun Pharma Communicable Diseases Drugs Basic Information
- 10.15.2 Sun Pharma Communicable Diseases Drugs Product Overview
- 10.15.3 Sun Pharma Communicable Diseases Drugs Product Market Performance
- 10.15.4 Sun Pharma Business Overview
- 10.15.5 Sun Pharma Recent Developments
- 10.16 Endo
 - 10.16.1 Endo Communicable Diseases Drugs Basic Information
 - 10.16.2 Endo Communicable Diseases Drugs Product Overview
 - 10.16.3 Endo Communicable Diseases Drugs Product Market Performance
 - 10.16.4 Endo Business Overview
 - 10.16.5 Endo Recent Developments
- 10.17 Apotex
 - 10.17.1 Apotex Communicable Diseases Drugs Basic Information
- 10.17.2 Apotex Communicable Diseases Drugs Product Overview
- 10.17.3 Apotex Communicable Diseases Drugs Product Market Performance
- 10.17.4 Apotex Business Overview
- 10.17.5 Apotex Recent Developments
- 10.18 Amneal Pharma
 - 10.18.1 Amneal Pharma Communicable Diseases Drugs Basic Information
 - 10.18.2 Amneal Pharma Communicable Diseases Drugs Product Overview
 - 10.18.3 Amneal Pharma Communicable Diseases Drugs Product Market Performance
 - 10.18.4 Amneal Pharma Business Overview
 - 10.18.5 Amneal Pharma Recent Developments
- 10.19 Torrent Pharma
 - 10.19.1 Torrent Pharma Communicable Diseases Drugs Basic Information
 - 10.19.2 Torrent Pharma Communicable Diseases Drugs Product Overview
 - 10.19.3 Torrent Pharma Communicable Diseases Drugs Product Market Performance
 - 10.19.4 Torrent Pharma Business Overview
 - 10.19.5 Torrent Pharma Recent Developments

11 COMMUNICABLE DISEASES DRUGS MARKET FORECAST BY REGION

- 11.1 Global Communicable Diseases Drugs Market Size Forecast
- 11.2 Global Communicable Diseases Drugs Market Forecast by Region
 - 11.2.1 North America Market Size Forecast by Country
 - 11.2.2 Europe Communicable Diseases Drugs Market Size Forecast by Country
 - 11.2.3 Asia Pacific Communicable Diseases Drugs Market Size Forecast by Region
 - 11.2.4 South America Communicable Diseases Drugs Market Size Forecast by

Country



11.2.5 Middle East and Africa Forecasted Consumption of Communicable Diseases Drugs by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)

- 12.1 Global Communicable Diseases Drugs Market Forecast by Type (2025-2032)
- 12.1.1 Global Forecasted Sales of Communicable Diseases Drugs by Type (2025-2032)
- 12.1.2 Global Communicable Diseases Drugs Market Size Forecast by Type (2025-2032)
- 12.1.3 Global Forecasted Price of Communicable Diseases Drugs by Type (2025-2032)
- 12.2 Global Communicable Diseases Drugs Market Forecast by Application (2025-2032)
 - 12.2.1 Global Communicable Diseases Drugs Sales (K Units) Forecast by Application
- 12.2.2 Global Communicable Diseases Drugs Market Size (M USD) Forecast by Application (2025-2032)

13 CONCLUSION AND KEY FINDINGS



List Of Tables

LIST OF TABLES

- Table 1. Introduction of the Type
- Table 2. Introduction of the Application
- Table 3. Market Size (M USD) Segment Executive Summary
- Table 4. Communicable Diseases Drugs Market Size Comparison by Region (M USD)
- Table 5. Global Communicable Diseases Drugs Sales (K Units) by Manufacturers (2019-2024)
- Table 6. Global Communicable Diseases Drugs Sales Market Share by Manufacturers (2019-2024)
- Table 7. Global Communicable Diseases Drugs Revenue (M USD) by Manufacturers (2019-2024)
- Table 8. Global Communicable Diseases Drugs Revenue Share by Manufacturers (2019-2024)
- Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Communicable Diseases Drugs as of 2022)
- Table 10. Global Market Communicable Diseases Drugs Average Price (USD/Unit) of Key Manufacturers (2019-2024)
- Table 11. Manufacturers Communicable Diseases Drugs Sales Sites and Area Served
- Table 12. Manufacturers Communicable Diseases Drugs Product Type
- Table 13. Global Communicable Diseases Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 14. Mergers & Acquisitions, Expansion Plans
- Table 15. Industry Chain Map of Communicable Diseases Drugs
- Table 16. Market Overview of Key Raw Materials
- Table 17. Midstream Market Analysis
- Table 18. Downstream Customer Analysis
- Table 19. Key Development Trends
- Table 20. Driving Factors
- Table 21. Communicable Diseases Drugs Market Challenges
- Table 22. Global Communicable Diseases Drugs Sales by Type (K Units)
- Table 23. Global Communicable Diseases Drugs Market Size by Type (M USD)
- Table 24. Global Communicable Diseases Drugs Sales (K Units) by Type (2019-2024)
- Table 25. Global Communicable Diseases Drugs Sales Market Share by Type (2019-2024)
- Table 26. Global Communicable Diseases Drugs Market Size (M USD) by Type (2019-2024)



- Table 27. Global Communicable Diseases Drugs Market Size Share by Type (2019-2024)
- Table 28. Global Communicable Diseases Drugs Price (USD/Unit) by Type (2019-2024)
- Table 29. Global Communicable Diseases Drugs Sales (K Units) by Application
- Table 30. Global Communicable Diseases Drugs Market Size by Application
- Table 31. Global Communicable Diseases Drugs Sales by Application (2019-2024) & (K Units)
- Table 32. Global Communicable Diseases Drugs Sales Market Share by Application (2019-2024)
- Table 33. Global Communicable Diseases Drugs Sales by Application (2019-2024) & (M USD)
- Table 34. Global Communicable Diseases Drugs Market Share by Application (2019-2024)
- Table 35. Global Communicable Diseases Drugs Sales Growth Rate by Application (2019-2024)
- Table 36. Global Communicable Diseases Drugs Sales by Region (2019-2024) & (K Units)
- Table 37. Global Communicable Diseases Drugs Sales Market Share by Region (2019-2024)
- Table 38. North America Communicable Diseases Drugs Sales by Country (2019-2024) & (K Units)
- Table 39. Europe Communicable Diseases Drugs Sales by Country (2019-2024) & (K Units)
- Table 40. Asia Pacific Communicable Diseases Drugs Sales by Region (2019-2024) & (K Units)
- Table 41. South America Communicable Diseases Drugs Sales by Country (2019-2024) & (K Units)
- Table 42. Middle East and Africa Communicable Diseases Drugs Sales by Region (2019-2024) & (K Units)
- Table 43. Global Communicable Diseases Drugs Production (K Units) by Region (2019-2024)
- Table 44. Global Communicable Diseases Drugs Revenue (US\$ Million) by Region (2019-2024)
- Table 45. Global Communicable Diseases Drugs Revenue Market Share by Region (2019-2024)
- Table 46. Global Communicable Diseases Drugs Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 47. North America Communicable Diseases Drugs Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)



Table 48. Europe Communicable Diseases Drugs Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 49. Japan Communicable Diseases Drugs Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 50. China Communicable Diseases Drugs Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 51. Novartis Communicable Diseases Drugs Basic Information

Table 52. Novartis Communicable Diseases Drugs Product Overview

Table 53. Novartis Communicable Diseases Drugs Sales (K Units), Revenue (M USD),

Price (USD/Unit) and Gross Margin (2019-2024)

Table 54. Novartis Business Overview

Table 55. Novartis Communicable Diseases Drugs SWOT Analysis

Table 56. Novartis Recent Developments

Table 57. Gilead Communicable Diseases Drugs Basic Information

Table 58. Gilead Communicable Diseases Drugs Product Overview

Table 59. Gilead Communicable Diseases Drugs Sales (K Units), Revenue (M USD),

Price (USD/Unit) and Gross Margin (2019-2024)

Table 60. Gilead Business Overview

Table 61. Gilead Communicable Diseases Drugs SWOT Analysis

Table 62. Gilead Recent Developments

Table 63. GSK Communicable Diseases Drugs Basic Information

Table 64. GSK Communicable Diseases Drugs Product Overview

Table 65. GSK Communicable Diseases Drugs Sales (K Units), Revenue (M USD),

Price (USD/Unit) and Gross Margin (2019-2024)

Table 66. GSK Communicable Diseases Drugs SWOT Analysis

Table 67. GSK Business Overview

Table 68. GSK Recent Developments

Table 69. Roche Communicable Diseases Drugs Basic Information

Table 70. Roche Communicable Diseases Drugs Product Overview

Table 71. Roche Communicable Diseases Drugs Sales (K Units), Revenue (M USD),

Price (USD/Unit) and Gross Margin (2019-2024)

Table 72. Roche Business Overview

Table 73. Roche Recent Developments

Table 74. Merck Communicable Diseases Drugs Basic Information

Table 75. Merck Communicable Diseases Drugs Product Overview

Table 76. Merck Communicable Diseases Drugs Sales (K Units), Revenue (M USD),

Price (USD/Unit) and Gross Margin (2019-2024)

Table 77. Merck Business Overview

Table 78. Merck Recent Developments



- Table 79. Boehringer Ingelheim Communicable Diseases Drugs Basic Information
- Table 80. Boehringer Ingelheim Communicable Diseases Drugs Product Overview
- Table 81. Boehringer Ingelheim Communicable Diseases Drugs Sales (K Units),
- Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 82. Boehringer Ingelheim Business Overview
- Table 83. Boehringer Ingelheim Recent Developments
- Table 84. Eli Lilly Communicable Diseases Drugs Basic Information
- Table 85. Eli Lilly Communicable Diseases Drugs Product Overview
- Table 86. Eli Lilly Communicable Diseases Drugs Sales (K Units), Revenue (M USD),
- Price (USD/Unit) and Gross Margin (2019-2024)
- Table 87. Eli Lilly Business Overview
- Table 88. Eli Lilly Recent Developments
- Table 89. AstraZeneca Communicable Diseases Drugs Basic Information
- Table 90. AstraZeneca Communicable Diseases Drugs Product Overview
- Table 91. AstraZeneca Communicable Diseases Drugs Sales (K Units), Revenue (M
- USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 92. AstraZeneca Business Overview
- Table 93. AstraZeneca Recent Developments
- Table 94. J and J Communicable Diseases Drugs Basic Information
- Table 95. J and J Communicable Diseases Drugs Product Overview
- Table 96. J and J Communicable Diseases Drugs Sales (K Units), Revenue (M USD),
- Price (USD/Unit) and Gross Margin (2019-2024)
- Table 97. J and J Business Overview
- Table 98. J and J Recent Developments
- Table 99. Teva Communicable Diseases Drugs Basic Information
- Table 100. Teva Communicable Diseases Drugs Product Overview
- Table 101. Teva Communicable Diseases Drugs Sales (K Units), Revenue (M USD),
- Price (USD/Unit) and Gross Margin (2019-2024)
- Table 102. Teva Business Overview
- Table 103. Teva Recent Developments
- Table 104. AbbVie Communicable Diseases Drugs Basic Information
- Table 105. AbbVie Communicable Diseases Drugs Product Overview
- Table 106. AbbVie Communicable Diseases Drugs Sales (K Units), Revenue (M USD),
- Price (USD/Unit) and Gross Margin (2019-2024)
- Table 107. AbbVie Business Overview
- Table 108. AbbVie Recent Developments
- Table 109. Bausch Health Communicable Diseases Drugs Basic Information
- Table 110. Bausch Health Communicable Diseases Drugs Product Overview
- Table 111. Bausch Health Communicable Diseases Drugs Sales (K Units), Revenue (M



- USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 112. Bausch Health Business Overview
- Table 113. Bausch Health Recent Developments
- Table 114. Abbott Communicable Diseases Drugs Basic Information
- Table 115. Abbott Communicable Diseases Drugs Product Overview
- Table 116. Abbott Communicable Diseases Drugs Sales (K Units), Revenue (M USD),
- Price (USD/Unit) and Gross Margin (2019-2024)
- Table 117. Abbott Business Overview
- Table 118. Abbott Recent Developments
- Table 119. Sanofi Communicable Diseases Drugs Basic Information
- Table 120. Sanofi Communicable Diseases Drugs Product Overview
- Table 121. Sanofi Communicable Diseases Drugs Sales (K Units), Revenue (M USD),
- Price (USD/Unit) and Gross Margin (2019-2024)
- Table 122. Sanofi Business Overview
- Table 123. Sanofi Recent Developments
- Table 124. Sun Pharma Communicable Diseases Drugs Basic Information
- Table 125. Sun Pharma Communicable Diseases Drugs Product Overview
- Table 126. Sun Pharma Communicable Diseases Drugs Sales (K Units), Revenue (M
- USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 127. Sun Pharma Business Overview
- Table 128. Sun Pharma Recent Developments
- Table 129. Endo Communicable Diseases Drugs Basic Information
- Table 130. Endo Communicable Diseases Drugs Product Overview
- Table 131. Endo Communicable Diseases Drugs Sales (K Units), Revenue (M USD),
- Price (USD/Unit) and Gross Margin (2019-2024)
- Table 132. Endo Business Overview
- Table 133. Endo Recent Developments
- Table 134. Apotex Communicable Diseases Drugs Basic Information
- Table 135. Apotex Communicable Diseases Drugs Product Overview
- Table 136. Apotex Communicable Diseases Drugs Sales (K Units), Revenue (M USD),
- Price (USD/Unit) and Gross Margin (2019-2024)
- Table 137. Apotex Business Overview
- Table 138. Apotex Recent Developments
- Table 139. Amneal Pharma Communicable Diseases Drugs Basic Information
- Table 140. Amneal Pharma Communicable Diseases Drugs Product Overview
- Table 141. Amneal Pharma Communicable Diseases Drugs Sales (K Units), Revenue
- (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 142. Amneal Pharma Business Overview
- Table 143. Amneal Pharma Recent Developments



Table 144. Torrent Pharma Communicable Diseases Drugs Basic Information

Table 145. Torrent Pharma Communicable Diseases Drugs Product Overview

Table 146. Torrent Pharma Communicable Diseases Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 147. Torrent Pharma Business Overview

Table 148. Torrent Pharma Recent Developments

Table 149. Global Communicable Diseases Drugs Sales Forecast by Region (2025-2032) & (K Units)

Table 150. Global Communicable Diseases Drugs Market Size Forecast by Region (2025-2032) & (M USD)

Table 151. North America Communicable Diseases Drugs Sales Forecast by Country (2025-2032) & (K Units)

Table 152. North America Communicable Diseases Drugs Market Size Forecast by Country (2025-2032) & (M USD)

Table 153. Europe Communicable Diseases Drugs Sales Forecast by Country (2025-2032) & (K Units)

Table 154. Europe Communicable Diseases Drugs Market Size Forecast by Country (2025-2032) & (M USD)

Table 155. Asia Pacific Communicable Diseases Drugs Sales Forecast by Region (2025-2032) & (K Units)

Table 156. Asia Pacific Communicable Diseases Drugs Market Size Forecast by Region (2025-2032) & (M USD)

Table 157. South America Communicable Diseases Drugs Sales Forecast by Country (2025-2032) & (K Units)

Table 158. South America Communicable Diseases Drugs Market Size Forecast by Country (2025-2032) & (M USD)

Table 159. Middle East and Africa Communicable Diseases Drugs Consumption Forecast by Country (2025-2032) & (Units)

Table 160. Middle East and Africa Communicable Diseases Drugs Market Size Forecast by Country (2025-2032) & (M USD)

Table 161. Global Communicable Diseases Drugs Sales Forecast by Type (2025-2032) & (K Units)

Table 162. Global Communicable Diseases Drugs Market Size Forecast by Type (2025-2032) & (M USD)

Table 163. Global Communicable Diseases Drugs Price Forecast by Type (2025-2032) & (USD/Unit)

Table 164. Global Communicable Diseases Drugs Sales (K Units) Forecast by Application (2025-2032)

Table 165. Global Communicable Diseases Drugs Market Size Forecast by Application



(2025-2032) & (M USD)



List Of Figures

LIST OF FIGURES

- Figure 1. Product Picture of Communicable Diseases Drugs
- Figure 2. Data Triangulation
- Figure 3. Key Caveats
- Figure 4. Global Communicable Diseases Drugs Market Size (M USD), 2019-2032
- Figure 5. Global Communicable Diseases Drugs Market Size (M USD) (2019-2032)
- Figure 6. Global Communicable Diseases Drugs Sales (K Units) & (2019-2032)
- Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 9. Evaluation Matrix of Regional Market Development Potential
- Figure 10. Communicable Diseases Drugs Market Size by Country (M USD)
- Figure 11. Communicable Diseases Drugs Sales Share by Manufacturers in 2023
- Figure 12. Global Communicable Diseases Drugs Revenue Share by Manufacturers in 2023
- Figure 13. Communicable Diseases Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
- Figure 14. Global Market Communicable Diseases Drugs Average Price (USD/Unit) of Key Manufacturers in 2023
- Figure 15. The Global 5 and 10 Largest Players: Market Share by Communicable Diseases Drugs Revenue in 2023
- Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 17. Global Communicable Diseases Drugs Market Share by Type
- Figure 18. Sales Market Share of Communicable Diseases Drugs by Type (2019-2024)
- Figure 19. Sales Market Share of Communicable Diseases Drugs by Type in 2023
- Figure 20. Market Size Share of Communicable Diseases Drugs by Type (2019-2024)
- Figure 21. Market Size Market Share of Communicable Diseases Drugs by Type in 2023
- Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 23. Global Communicable Diseases Drugs Market Share by Application
- Figure 24. Global Communicable Diseases Drugs Sales Market Share by Application (2019-2024)
- Figure 25. Global Communicable Diseases Drugs Sales Market Share by Application in 2023
- Figure 26. Global Communicable Diseases Drugs Market Share by Application (2019-2024)
- Figure 27. Global Communicable Diseases Drugs Market Share by Application in 2023



- Figure 28. Global Communicable Diseases Drugs Sales Growth Rate by Application (2019-2024)
- Figure 29. Global Communicable Diseases Drugs Sales Market Share by Region (2019-2024)
- Figure 30. North America Communicable Diseases Drugs Sales and Growth Rate (2019-2024) & (K Units)
- Figure 31. North America Communicable Diseases Drugs Sales Market Share by Country in 2023
- Figure 32. U.S. Communicable Diseases Drugs Sales and Growth Rate (2019-2024) & (K Units)
- Figure 33. Canada Communicable Diseases Drugs Sales (K Units) and Growth Rate (2019-2024)
- Figure 34. Mexico Communicable Diseases Drugs Sales (Units) and Growth Rate (2019-2024)
- Figure 35. Europe Communicable Diseases Drugs Sales and Growth Rate (2019-2024) & (K Units)
- Figure 36. Europe Communicable Diseases Drugs Sales Market Share by Country in 2023
- Figure 37. Germany Communicable Diseases Drugs Sales and Growth Rate (2019-2024) & (K Units)
- Figure 38. France Communicable Diseases Drugs Sales and Growth Rate (2019-2024) & (K Units)
- Figure 39. U.K. Communicable Diseases Drugs Sales and Growth Rate (2019-2024) & (K Units)
- Figure 40. Italy Communicable Diseases Drugs Sales and Growth Rate (2019-2024) & (K Units)
- Figure 41. Russia Communicable Diseases Drugs Sales and Growth Rate (2019-2024) & (K Units)
- Figure 42. Asia Pacific Communicable Diseases Drugs Sales and Growth Rate (K Units)
- Figure 43. Asia Pacific Communicable Diseases Drugs Sales Market Share by Region in 2023
- Figure 44. China Communicable Diseases Drugs Sales and Growth Rate (2019-2024) & (K Units)
- Figure 45. Japan Communicable Diseases Drugs Sales and Growth Rate (2019-2024) & (K Units)
- Figure 46. South Korea Communicable Diseases Drugs Sales and Growth Rate (2019-2024) & (K Units)
- Figure 47. India Communicable Diseases Drugs Sales and Growth Rate (2019-2024) &



(K Units)

Figure 48. Southeast Asia Communicable Diseases Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 49. South America Communicable Diseases Drugs Sales and Growth Rate (K Units)

Figure 50. South America Communicable Diseases Drugs Sales Market Share by Country in 2023

Figure 51. Brazil Communicable Diseases Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 52. Argentina Communicable Diseases Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 53. Columbia Communicable Diseases Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 54. Middle East and Africa Communicable Diseases Drugs Sales and Growth Rate (K Units)

Figure 55. Middle East and Africa Communicable Diseases Drugs Sales Market Share by Region in 2023

Figure 56. Saudi Arabia Communicable Diseases Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 57. UAE Communicable Diseases Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 58. Egypt Communicable Diseases Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 59. Nigeria Communicable Diseases Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 60. South Africa Communicable Diseases Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 61. Global Communicable Diseases Drugs Production Market Share by Region (2019-2024)

Figure 62. North America Communicable Diseases Drugs Production (K Units) Growth Rate (2019-2024)

Figure 63. Europe Communicable Diseases Drugs Production (K Units) Growth Rate (2019-2024)

Figure 64. Japan Communicable Diseases Drugs Production (K Units) Growth Rate (2019-2024)

Figure 65. China Communicable Diseases Drugs Production (K Units) Growth Rate (2019-2024)

Figure 66. Global Communicable Diseases Drugs Sales Forecast by Volume (2019-2032) & (K Units)



Figure 67. Global Communicable Diseases Drugs Market Size Forecast by Value (2019-2032) & (M USD)

Figure 68. Global Communicable Diseases Drugs Sales Market Share Forecast by Type (2025-2032)

Figure 69. Global Communicable Diseases Drugs Market Share Forecast by Type (2025-2032)

Figure 70. Global Communicable Diseases Drugs Sales Forecast by Application (2025-2032)

Figure 71. Global Communicable Diseases Drugs Market Share Forecast by Application (2025-2032)



I would like to order

Product name: Global Communicable Diseases Drugs Market Research Report 2024, Forecast to 2032

Product link: https://marketpublishers.com/r/G6C4E197AAC5EN.html

Price: US\$ 3,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G6C4E197AAC5EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970